RT Journal Article
SR Electronic
T1 The influence of human genetic variation on Epstein-Barr virus sequence diversity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.02.20242370
DO 10.1101/2020.12.02.20242370
A1 Rüeger, Sina
A1 Hammer, Christian
A1 Loetscher, Alexis
A1 McLaren, Paul J
A1 Lawless, Dylan
A1 Naret, Olivier
A1 Depledge, Daniel P.
A1 Morfopoulou, Sofia
A1 Breuer, Judith
A1 Zdobnov, Evgeny
A1 Fellay, Jacques
A1 Swiss HIV Cohort Study
YR 2020
UL http://medrxiv.org/content/early/2020/12/06/2020.12.02.20242370.abstract
AB Epstein-Barr virus (EBV) is one of the most common viruses latently infecting humans. Little is known about the impact of human genetic variation on the large inter-individual differences observed in response to EBV infection. To search for a potential imprint of host genomic variation on the EBV sequence, we jointly analyzed paired viral and human genomic data from 268 HIV-coinfected individuals with CD4+ T cell count <200/mm3 and elevated EBV viremia. We hypothesized that the reactivated virus circulating in these patients could carry sequence variants acquired during primary EBV infection, thereby providing a snapshot of early adaptation to the pressure exerted on EBV by the individual immune response. We searched for associations between host and pathogen genetic variants, taking into account human and EBV population structure. Our analyses revealed significant associations between human and EBV sequence variation. Three polymorphic regions in the human genome were found to be associated with EBV variation: one at the amino acid level (BRLF1:p.Lys316Glu); and two at the gene level (burden testing of rare variants in BALF5 and BBRF1). Our findings confirm that jointly analyzing host and pathogen genomes can identify sites of genomic interactions, which could help dissect pathogenic mechanisms and suggest new therapeutic avenues.Competing Interest StatementCH is an employee of Genentech.Funding StatementThis study was supported by the Leenaards Foundation (Leenaards Prize 2015 to JF and EZ). This study has also been partly financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (grant #177499), by SHCS project #743 and by the SHCS research foundation. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SHCS has been approved by the Ethics Committees of all participating institutions. Each study participant provided written informed consent for genetic testing.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available in the following Zenodo repositories: G2G results are in https://doi.org/10.5281/zenodo.4289138, pathogen data in https://doi.org/10.5281/zenodo.4011995. https://doi.org/10.5281/zenodo.4011995 https://doi.org/10.5281/zenodo.4289138